Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Cisplatin with Ivosidenib or Pemigatinib in Advanced Cholangiocarcinoma
NCT04088188Phase 1Terminated
- Sponsor
- Academic and Community Cancer Research United
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of ivosidenib and pemigatinib in cholangiocarcinoma (CCA), sponsored by Academic and Community Cancer Research United. Primary endpoint: Number of Participants With Significant Toxicities at 3 weeks. Started Jan 2021; status: terminated.
02
Drugs
ivosidenibpemigatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04088188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088188.